Mike Klein, a veteran of the Ann Arbor tech community, is the CEO of Genomenon Inc., a 2014 spinoff from the University of Michigan that focuses on using genome interpretation software to help provide personalized medicine. With over 25 years of developing, building and growing 4 different high tech companies, Mike has raised over $50M in capital and had several successful investor exits.